Zusammenfassung
Der Ginkgo-Spezialextrakt EGb 761 greift in Pathomechanismen demenzieller Erkrankungen ein, wie Aβ-Aggregation, Störung der Mitochondrienfunktion, Insulinresistenz und Hypoperfusion. Die Wirksamkeit von EGb 761 bei demenziellen Erkrankungen (Alzheimer-Krankheit, vaskuläre Demenz) wurde in 10 randomisierten, kontrollierten Doppelblindstudien untersucht. In 3 der 4 großen, nach aktuellen Empfehlungen durchgeführten Studien, war EGb 761 dem Placebo hinsichtlich der kognitiven Leistung sowie einer oder mehrerer weiteren Messgrößen (global, funktionell oder psychopathologisch), die die klinische Relevanz der Effekte belegen, signifikant überlegen. Die Ergebnisse der 6 kleineren Studien stehen damit im Einklang. Eine Studie war inkonklusiv, wegen ungewöhnlich rigoroser Patientenselektion aber von fraglicher externer Validität. Subgruppenanalysen dieser Studie sowie die Ergebnisse der neuesten Studie legen nahe, dass Patienten mit neuropsychiatrischen Symptomen, die die Mehrheit der Demenzpatienten darstellen, am meisten von der Behandlung mit EGb 761 profitieren. Verzögerung der Symptomprogression, Responseraten und Numbers Needed to Treat (NNT) liegen für EGb 761 in derselben Größenordnung wie für Cholinesterasehemmer. Eine exploratorische Studie zum Vergleich von EGb 761 und Donepezil zeigte keine statistisch signifikanten oder klinisch relevanten Unterschiede. Damit hat EGb 761 zu Recht seinen Platz in der Behandlung von Patienten mit Demenz.
Abstract
The Ginkgo biloba extract EGb 761 interferes with pathomechanisms relevant to dementia, such as Aβ aggregation, mitochondrial dysfunction, insulin resistance, and hypoperfusion. The efficacy of EGb 761 in the treatment of dementia (Alzheimer’s disease and vascular dementia) has been studied in 10 randomised, controlled, double-blind clinical trials. In three of the four large trials conducted in accordance with recent recommendations EGb 761 was significantly superior to placebo with respect to cognitive performance and one or more further (global, functional or behavioural) outcomes demonstrating the clinical relevance of the findings. The findings from the six smaller trials are in line with those of the large trials. One trial was inconclusive, but of questionable external validity due to uncommonly rigorous patient selection. Subgroup analyses of this study together with the findings from the most recent clinical trial suggest that EGb 761 may be most beneficial to patients with neuropsychiatric symptoms, who actually constitute the majority of dementia patients. Delay in symptom progression, rates of clinically significant treatment response and numbers needed to treat (NNT) found for EGb 761 are in the same range as those reported for cholinesterase inhibitors. In an exploratory trial comparing EGb 761 and donepezil, no statistically significant or clinically relevant differences were seen. Hence, EGb 761 has its place in the treatment of dementia.
Schlüsselwörter
Demenz - Alzheimer - vaskuläre Demenz - Ginkgo biloba - EGb 761 - Review
Key words
dementia - Alzheimer’s disease - vascular dementia - Ginkgo biloba - EGb 761 - review
Literatur
-
1
Barth S A, Inselmann G, Engemann R. et al .
Influences of Ginkgo biloba on Cyclosporin A induced lipid peroxidation in human liver microsomes in comparison to vitamin E, Glutathione and N-Acetylcysteine.
Biochem Pharmacol.
1991;
41
1521-1526
-
2
Dumont E, Petit E, Tarrade T. et al .
UV-C irradiation-induced peroxidative degradation of microsomal fatty acids and proteins: protection by an extract of Ginkgo biloba (EGb 761).
Free Radic Biol Med.
1992;
13
197-203
-
3
Karcher L, Zagermann P, Krieglstein J.
Effects of an extract of Ginkgo biloba on rat brain energy metabolism in hypoxia.
Naunyn-Schmiedebergs Arch Pharmacol.
1984;
327
31-35
-
4
Spinnewyn B, Blavet N, Clostre F.
Effets de l’extrait de Ginkgo biloba sur un modèle d’ischémie cérébrale chez la gerbille.
Presse Med.
1986;
15
1511-1515
-
5
Sastre J, Millán A, García d la Asunción J. et al .
A Ginkgo biloba extract (EGb 761®) prevents mitochondrial aging by protecting against oxidative stress.
Free Radic Biol Med.
1998;
24
298-304
-
6
Eckert A, Keil U, Kressmann S. et al .
Effects of EGb 761® Ginkgo biloba extract on mitochondrial function and oxidative stress.
Pharmacopsychiatry.
2003;
36 (Suppl 1)
S15-S23
-
7
Hoyer S, Lannert H, Nöldner M. et al .
Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761).
J Neural Transm.
1999;
106
1171-1188
-
8
Luo Y, Smith J V, Paramasivam V. et al .
Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb 761®.
Proc Natl Acad Sci U S A.
2002;
99
12197-12202
-
9
Wu Y, Wu Z, Butko P. et al .
Amyloid-β-induced pathological behaviours are suppressed by Ginkgo biloba extract EGb 761® and ginkgolides in transgenic Caenorhabditis elegans.
J Neurosc.
2006;
26
13102-13113
-
10
Bastianetto S, Ramassamy C, Doré S. et al .
The Ginkgo biloba extract (EGb 761®) protects hippocampal neurons against cell death induced by ß-amyloid.
Eur J Neurosci.
2000;
12
1882-1890
-
11
Smith J V, Luo Y.
Elevation of oxidative free radicals in Alzheimer’s disease models can be attenuated by Ginkgo biloba extract EGb 761®.
J Alzheimers Dis.
2003;
5
287-300
-
12 Taylor J E. The effects of chronic, oral Ginkgo biloba extract administration on neurotransmitter receptor binding in young and aged Fisher 344 rats. Agnoli A, Rapin J R, Scapagnini V, Weitbrecht WU Effects of Ginkgo Biloba Extract on Organic Cerebral Impairment Montrouge; John Libbey Eurotext 1985: 31-34
-
13
Huguet F, Drieu K, Piriou A.
Decreased cerebral 5-HT1A receptors during aging: reversal by Ginkgo biloba Extract (EGb 761).
J Pharm Pharmacol.
1994;
46
316-318
-
14
Krištofiková Z, Benešová O, Tejkalová H.
Changes of high-affinity choline uptake in the hippocampus of old rats after long-term administration of two nootropic drugs (Tacrine and Ginkgo biloba extract).
Dementia.
1992;
3
304-307
-
15
Winter E.
Effects of an Extract of Ginkgo Biloba on Learning and Memory in Mice.
Pharmacol Biochem Behav.
1991;
38
109-114
-
16
Rapin J R, Lamproglou I, Drieu K. et al .
Demonstration of the „anti-stress” activity of an extract of Ginkgo biloba (EGb 761®) using a discrimination learning task.
Gen Pharmacol.
1994;
25
1009-1016
-
17
Reddy P H, Beal M F.
Are mitochondria critical in the pathogenesis of Alzheimer’s disease?.
Brain Res Rev.
2005;
49
618-632
-
18
Onyango I G, Khan S M.
Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer’s disease.
Curr Alzheimer Res.
2006;
3
339-349
-
19
Monte S M, Wands J R.
Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer’s disease.
J Alzheimers Dis.
2005;
7
45-61
-
20
Razay de la G, Vreugdenhil A, Wilcock G.
The metabolic syndrome and Alzheimer disease.
Arch Neurol.
2007;
64
93-96
-
21
Hoozemans J JM, Chafekar S M, Baas F. et al .
Always around, never the same: Pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer’s disease.
Curr Med Chem.
2006;
13
2599-2605
-
22
Klein W L.
Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer’s disease.
Alzheimers Dement.
2006;
2
43-55
-
23
Walsh D M, Selkoe D J.
A beta oligomers - a decade of discovery.
J Neurochem.
2007;
101
1172-1184
-
24
Költringer P, Langsteger W, Ober O.
Dose-dependent hemorheological effects and microcirulatory modifications following intravenous administration of Ginkgo biloba special extract EGb 761.
Clin Hemorheol.
1995;
15
649-656
-
25
Erdinçler D S, Karakoç Y, Toplan S. et al .
The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability.
Clin Hemorheol.
1996;
16
271-276
-
26
Heiss W D, Zeiler K.
Medikamentöse Beeinflussung der Hirndurchblutung.
Pharmakotherapie.
1978;
1
137-144
-
27 Luthringer R, d’Arbigny P, Macher J P. Ginkgo biloba extract (EGb 761), EEG and event-related potentials. Christen Y, Courtois Y, Droy-Lefaix MT Advances in Ginkgo biloba extract research, vol. 4. Effects of Ginkgo biloba on aging and age-related disorders Paris; Elsevier 1995: 107-118
-
28
Itil T M, Eralp E, Tsambis E. et al .
Central nervous system effects of Ginkgo biloba, a plant extract.
Am J Ther.
1996;
3
63-73
-
29
Fourtillan J B, Brisson A M, Girault J. et al .
Propriété pharmacocinétique du Bilobalide et des Ginkgolides A et B chez le sujet sain après administrations intraveineuses et orales d’extrait de Ginkgo biloba (EGb 761®).
Therapie.
1995;
50
137-144
-
30
Birks J, Grimley Evans J.
Ginkgo biloba for cognitive impairment and dementia.
Cochrane Database Syst Rev.
2002;
Issue 4. Art. No.: CD 003120
DOI: 10.1002/14651 858.CD 003120
-
31
Birks J, Grimley Evans J.
Ginkgo biloba for cognitive impairment and dementia.
Cochrane Database Syst Rev.
2007;
Issue 2. Art. No.: CD 003120
DOI: 10.1002/14651858.CD 003120.pub2
-
32
Napryeyenko O, Borzenko I. for the GINDEM-NP Study Group .
Ginkgo biloba special extract in dementia with neuropsychiatric features.
Arzneimittelforschung.
2007;
57
4-11
-
33
Napryeyenko O, Sonnik G, Tartakovsky I.
Efficacy and tolerability of Ginkgo biloba extract EGb 761® by type of dementia: Analyses of a randomised controlled trial.
J Neurol Sci.
2009;
doi: 10.1016/j.jns.2009.02.353
-
34
Schneider L S, DeKosky S T, Farlow M R. et al .
A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type.
Curr Alzheimer Res.
2005;
2
541-551
-
35
Kanowski S, Herrmann W M, Stephan K. et al .
Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
Pharmacopsychiatry.
1996;
29
47-56
-
36
Kanowski S, Hoerr R.
Ginkgo biloba extract EGb 761® in dementia: Intent-to-treat analyses of a 24-week, multi-centre, double-blind, placebo-controlled, randomised trial.
Pharmacopsychiatry.
2003;
36
297-303
-
37
Le Bars P L, Katz M M, Berman N. et al .
A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia.
JAMA.
1997;
278
1327-1332
-
38
Le Bars P L, Kieser M, Itil K Z.
A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia.
Dement Geriatr Cogn Disord.
2000;
11
230-237
-
39
Le Bars P L, Velasco F M, Ferguson J M. et al .
Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer’s disease.
Neuropsychobiology.
2002;
45
19-26
-
40
Maurer K, Ihl R, Dierks T. et al .
Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type.
J Psychiatr Res.
1997;
31
645-655
-
41
Hofferberth B.
The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation.
Hum Psychopharmacol.
1994;
9
215-222
-
42
Mancini M, Agozzino B, Bompani R.
Effetti clinico-terapeutici dell’estratto di Ginkgo biloba (EGb) in confronto a placebo, nel trattamento di pazienti affetti da demenza psicorganica senile su base arteriosclerotica.
Gazz Med Ital – Arch Sci Med.
1993;
152
69-80
-
43
Weitbrecht W U, Jansen W.
Primär degenerative Demenz: Therapie mit Ginkgo-biloba-Extrakt. Placebokontrollierte Doppelblind- und Vergleichsstudie.
Fortschr Med.
1986;
104
199-202
-
44
Haase J, Halama P, Hörr R.
Wirksamkeit kurzdauernder Infusionsbehandlungen mit Ginkgo-biloba-Spezialextrakt EGb 761® bei Demenz vom vaskulären und Alzheimer-Typ.
Z Gerontol Geriat.
1996;
29
302-309
-
45
Yancheva S, Ihl R, Nikolova G. et al .
Ginkgo biloba Extract EGb 761®, donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: A randomised, double-blind, exploratory trial.
Aging Ment Health.
2009;
13
183-190
-
46 Leber P. Guidelines for the clinical evaluation of antidementia drugs. First draft. Rockville, MD; US Food and Drug Administration 1990
-
47 Committee for Proprietary Medicinal Products (CPMP) .Note for guidance on medicinal products in the treatment of Alzheimer’s disease. London; The European Agency for the Evaluation of Medicinal Products 1997
-
48
Ihl R, Grass-Kapanke B, Jänner M. et al .
Neuropsychometric tests in cross sectional and longitudinal studies – a regression analysis of ADAS-cog, SKT and MMSE.
Pharmacopsychiatry.
1999;
32
248-354
-
49
Schneider L S, Olin J T, Lyness S A. et al .
Eligibility of Alzheimer’s disease clinic patients for clinical trials.
J Am Geriatr Soc.
1997;
45
923-928
-
50
Lyketsos C G, Lopez O, Jones B. et al .
Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. Results from the Cardiovascular Health Study.
JAMA.
2002;
288
1475-1483
-
51
Letzel H, Haan J, Feil W B.
Nootropics: Efficacy and tolerability of products from three active substance classes.
Journal of Drug Development and Clinical Practice.
1996;
8
77-94
-
52
Oken B S, Storzbach D M, Kaye J A.
The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.
Arch Neurol.
1998;
55
1409-1415
-
53
Ernst E, Pittler M H.
Ginkgo biloba for dementia. A systematic review of double-blind, placebo-controlled trials.
Clin Drug Investig.
1999;
17
301-308
-
54 IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen .Ginkgohaltige Präparate bei Alzheimer Demenz. Abschlussbericht. Auftrag A 05 – 19B, Version 1.0. IQWiG IQWiG-Berichte – Jahr: 2008 Nr.39 Köln; IQWiG 2008 http://www.iqwig.de/download/A05 – 19B_Abschlussbericht_Ginkgohaltige_Praeparate_bei_Alzheimer_Demenz.pdf (Zugriff am 14.4.2009)
-
55
DeKosky S T, Williamson J D, Fitzpatrick A L. et al .
Ginkgo biloba for prevention of dementia. A randomized controlled trial.
JAMA.
2008;
300
2253-2262
-
56
Hoerr R.
Treatment effects of EGb 761® and cholinesterase inhibitors – why available studies do not demonstrate superiority of the latter.
Phytomedicine.
2005;
12
598-600
-
57
Wettstein A.
Cholinesterasehemmer und Ginkgoextrakte – in der Demenztherapie vergleichbar?.
Fortschr Med.
1999;
117
11-18
-
58
Knapp M J, Knopman D S, Solomon P R. et al .
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease.
JAMA.
1994;
271
985-991
-
59
Rogers S l, Farlow M R, Doody R S. et al .
A 24 week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease.
Neurology.
1998;
50
136-145
-
60
Corey-Bloom J, Anand R, Veach for the ENA 713 B 352 Study Group J.
A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease.
International Journal of Geriatric Psychopharmacology.
1998;
1
55-65
-
61
Rösler M, Anand R, Cicin-Sain A. et al .
Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial.
Br Med J.
1999;
318
633-640
-
62
Raskind M A, Peskind E R, Wessel T. et al .
A 6-month randomized, placebo-controlled trial with a 6-month extension.
Neurology.
2000;
54
2261-2268
-
63
Tariot P N, Solomon P R, Morris J C. et al .
A 5-month, randomized, placebo-controlled trial of galantamine in AD.
Neurology.
2000;
54
2269-2276
-
64
Wilcock G K, Lilienfeld S, Gaens E. et al .
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial.
Br Med J.
2000;
321
1445-1449
-
65 Bandolier N N. „Evidence based thinking about health care”. Number needed to treat (NNT). Bandolier 59 January 1999 Accessible at http://www.jr2.ox.ac.uk/bandolier/band59/NNT1.html. Last access 16.06.2009
-
66
Bullock R, Touchon J, Bergmann H. et al .
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period.
Curr Med Res Opin.
2005;
12
1317-1327
-
67
Bancher C, Croy A, Dal Bianco P. et al .
Österreichisches Alzheimer-Krankheit-Konsensus.
Neuropsychiatr,.
1998;
12
126-167
-
68
Alf C, Bancher C, Benke T. et al .
Konsensusstatement „Demenz” der Österreichischen Alzheimer-Gesellschaft und der Österreichischen Alzheimer-Liga.
Neuropsychiatr.
2004;
18
39-46
-
69 Kasper S, Kalousek M, Saletu B. et al .Demenzerkrankungen Medikamentöse Therapie. Konsensus-Statement – State of the Art 2006. CliniCum psy Sonderausgabe November 2006 Wien; Medizin Medien Austria
-
70 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde DGPPN .Praxisleitlinien in Psychiatrie und Psychotherapie Band 3, Behandlungsleitlinie Demenz. Darmstadt; Steinkopff 2000: 26-29
O. Univ. Prof. Dr. DDr. h. c. Siegfried Kasper
Universitätsklinik für Psychiatrie und PsychotherapieMedizinische Universität Wien
Währinger Gürtel 18 – 20
1090 Wien
Österreich
Email: sci-biolpsy@meduniwien.ac.at
